カテゴリ： GlobalData, ドイツ, 企業調査

Grunenthal GmbH：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Grunenthal GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C0464
◆発行会社（調査会社）：GlobalData
◆発行日：2018年7月
◆ページ数：68
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：ドイツ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Grunenthal GmbH (Grunenthal) is a research-oriented pharmaceutical company. It researches, develops, produces and markets products for the treatment of pain and innovative formulations of established active substances. The company provides new chemical entities including opioids for moderate to severe pain, vanilloid receptors and KCNQ channel openers for chronic neuropathic pain; and the Bradykinin receptor for the treatment of chronic diseases with inflammation. Grunenthal also focuses on discovering new methods to treat pain, developing new medical devices, and new platform technologies for drug delivery. The company operates along with its subsidiaries in Europe, Latin America and the US. Grunenthal is headquartered in Aachen, Germany.

Grunenthal GmbH – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Grunenthal GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Grunenthal GmbH, Medical Devices Deals, 2012 to YTD 2018 11
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
Grunenthal Acquires Rights to Zomic from AstraZeneca 15
Grunenthal to Acquire Qutenza from Astellas Pharma Europe 16
Grunenthal Acquires Portfolio of Pharma Drugs from Biogen Labs 17
Venture Financing 18
Thar Pharma Raises USD0.12 Million in Venture Financing 18
Thar Pharma Raises Additional USD2 Million in Venture Financing 19
Thar Pharma Raises Additional USD1.54 Million in Venture Financing 20
Thar Pharma Raises Additional US$0.08 Million In Venture Financing 21
Partnerships 22
Grunenthal, Lead Discovery Center, Max-Planck Innovation and Max Planck Institute of Experimental Medicine Enter into Agreement 22
Grunenthal and KU Leuven Enter into Research Agreement 24
Grunenthal Enters into Distribution Agreement with Merck 25
Helsinn and Grunenthal Enter into Agreement for Akynzeo 26
Grunenthal Enters into Agreement with Axxam 27
Patheon Enters into Co-Development Agreement with Grunenthal 28
Grunenthal Enters into Co-Development Agreement with Akashi Therapeutics 29
Thar Pharma Enters into Co-Development Agreement 30
Grunenthal, Nordic Bioscience and Argenta Discovery Enter into Research Agreement 31
Ayoxxa Biosystems Completes Research Collaboration With Grunenthal 32
Grunenthal Enters into Agreement with Proteus and Boston Children’s Hospital 33
Cipher Pharma Enters into Distribution Agreement with Laboratorios Andromaco for Isotretinoin Product 34
AcelRx Pharma Amends Commercialization Agreement With Grunenthal For Zalviso 35
Grunenthal Enters Into Agreement With Amura Therapeutics To Develop Protease Inhibitors For Pain and Inflammation 37
Licensing Agreements 38
Mundipharma Enters into Licensing Agreement with Grunenthal 38
Grunenthal Enters into Licensing Agreement with AstraZeneca 39
Mundipharma Enters Into Licensing Agreement With Grunenthal 40
Endo Pharma Holdings Amends Licensing Agreement with Grunenthal 41
Grunenthal Enters into Licensing Agreement with Abiogen Pharma 42
Grunenthal Enters Into Licensing Agreement With Purdue Pharma For IP Rights To Abuse-Deterrent Formulation Technology 43
Grunenthal Enters Into Licensing Agreement With Ethypharm For Fentanyl Sublingual Tablets 44
Grunenthal Enters Into Licensing Agreement With Horizon Pharma For Duexis 45
BioClinica Enters Into Licensing Agreement With Grunenthal For BioClinica OnPoint CTMS 46
Equity Offering 47
Thar Pharma Postpones IPO for USD50 Million 47
Asset Transactions 49
Depomed Acquires Rights of Cebranopadol from Grunenthal 49
STADA Completes Acquisition Of Branded Product Portfolio In Central Europe From Grunenthal For US$230 Million 51
Acquisition 53
Grunenthal Acquires Thar Pharma 53
Grunenthal Group to Acquire Almirall de Mexico for USD33.4 Million 54
Grunenthal Acquires 81.59% Stake in Laboratorios Andromaco 55
Grunenthal Plans To Acquire Pain Therapeutics Company In Latin America 56
Grunenthal GmbH – Key Competitors 57
Grunenthal GmbH – Key Employees 58
Grunenthal GmbH – Locations And Subsidiaries 59
Head Office 59
Other Locations & Subsidiaries 59
Recent Developments 62
Strategy And Business Planning 62
May 10, 2017: Grünenthal Opens Innovation Hub in Boston as Next Step in Strategy to Drive External Innovation in Pain, Specialty Therapeutics and Medical Devices Forward 62
Corporate Communications 63
Sep 01, 2017: Mark Fladrich Takes office as the New CCO of the Grunenthal Group 63
May 09, 2017: Mark Fladrich Appointed New Chief Commercial Officer at Grunenthal 64
Government and Public Interest 65
Nov 16, 2017: Research Consortium led by Grünenthal receives € 2 million grant from the European Fund for Regional Development and the State of North Rhine-Westphalia 65
May 23, 2017: Cutting Edge Science in Pain Treatment in Order to Improve Patients’ Lives – EFIC-GRUNENTHAL GRANT 2016 Supports Six Young Scientists in Their Advanced Pain Research Projects 66
Product News 67
Jul 07, 2017: Grünenthal Group: Launch of the Project – Modelling Neuron-glia Networks Into a Drug Discovery Platform for Pain Efficacious Treatments (NGN-PET) 67
Appendix 68
Methodology 68
About GlobalData 68
Contact Us 68
Disclaimer 68

List of Tables
Grunenthal GmbH, Pharmaceuticals & Healthcare, Key Facts 2
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Grunenthal GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Grunenthal GmbH, Deals By Therapy Area, 2012 to YTD 2018 10
Grunenthal GmbH, Medical Devices Deals, 2012 to YTD 2018 11
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Grunenthal Acquires Rights to Zomic from AstraZeneca 15
Grunenthal to Acquire Qutenza from Astellas Pharma Europe 16
Grunenthal Acquires Portfolio of Pharma Drugs from Biogen Labs 17
Thar Pharma Raises USD0.12 Million in Venture Financing 18
Thar Pharma Raises Additional USD2 Million in Venture Financing 19
Thar Pharma Raises Additional USD1.54 Million in Venture Financing 20
Thar Pharma Raises Additional US$0.08 Million In Venture Financing 21
Grunenthal, Lead Discovery Center, Max-Planck Innovation and Max Planck Institute of Experimental Medicine Enter into Agreement 22
Grunenthal and KU Leuven Enter into Research Agreement 24
Grunenthal Enters into Distribution Agreement with Merck 25
Helsinn and Grunenthal Enter into Agreement for Akynzeo 26
Grunenthal Enters into Agreement with Axxam 27
Patheon Enters into Co-Development Agreement with Grunenthal 28
Grunenthal Enters into Co-Development Agreement with Akashi Therapeutics 29
Thar Pharma Enters into Co-Development Agreement 30
Grunenthal, Nordic Bioscience and Argenta Discovery Enter into Research Agreement 31
Ayoxxa Biosystems Completes Research Collaboration With Grunenthal 32
Grunenthal Enters into Agreement with Proteus and Boston Children's Hospital 33
Cipher Pharma Enters into Distribution Agreement with Laboratorios Andromaco for Isotretinoin Product 34
AcelRx Pharma Amends Commercialization Agreement With Grunenthal For Zalviso 35
Grunenthal Enters Into Agreement With Amura Therapeutics To Develop Protease Inhibitors For Pain and Inflammation 37
Mundipharma Enters into Licensing Agreement with Grunenthal 38
Grunenthal Enters into Licensing Agreement with AstraZeneca 39
Mundipharma Enters Into Licensing Agreement With Grunenthal 40
Endo Pharma Holdings Amends Licensing Agreement with Grunenthal 41
Grunenthal Enters into Licensing Agreement with Abiogen Pharma 42
Grunenthal Enters Into Licensing Agreement With Purdue Pharma For IP Rights To Abuse-Deterrent Formulation Technology 43
Grunenthal Enters Into Licensing Agreement With Ethypharm For Fentanyl Sublingual Tablets 44
Grunenthal Enters Into Licensing Agreement With Horizon Pharma For Duexis 45
BioClinica Enters Into Licensing Agreement With Grunenthal For BioClinica OnPoint CTMS 46
Thar Pharma Postpones IPO for USD50 Million 47
Depomed Acquires Rights of Cebranopadol from Grunenthal 49
STADA Completes Acquisition Of Branded Product Portfolio In Central Europe From Grunenthal For US$230 Million 51
Grunenthal Acquires Thar Pharma 53
Grunenthal Group to Acquire Almirall de Mexico for USD33.4 Million 54
Grunenthal Acquires 81.59% Stake in Laboratorios Andromaco 55
Grunenthal Plans To Acquire Pain Therapeutics Company In Latin America 56
Grunenthal GmbH, Key Competitors 57
Grunenthal GmbH, Key Employees 58
Grunenthal GmbH, Other Locations 59
Grunenthal GmbH, Subsidiaries 59

List of Figures
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Grunenthal GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Grunenthal GmbH, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Grunenthal GmbH：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Provogue (India) Limited (PROVOGE)：企業の財務・戦略的SWOT分析
    Provogue (India) Limited (PROVOGE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Collegium Pharmaceutical Inc (COLL)：製薬・医療：M&Aディール及び事業提携情報
    Summary Collegium Pharmaceutical Inc (Collegium) is a specialty pharmaceutical company that focuses on the development and commercialization of innovative products for treating patients suffering from pain. The company develops products based on its DETERx platform technology. DETERx offers extended …
  • AMETEK, Inc.：企業の戦略・SWOT・財務情報
    AMETEK, Inc. - Strategy, SWOT and Corporate Finance Report Summary AMETEK, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Wistron Corporation：企業の戦略・SWOT・財務分析
    Wistron Corporation - Strategy, SWOT and Corporate Finance Report Summary Wistron Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Indian Oil Corporation Limited：企業の戦略・SWOT・財務情報
    Indian Oil Corporation Limited - Strategy, SWOT and Corporate Finance Report Summary Indian Oil Corporation Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Wallenstam AB (WALL B)：企業の財務・戦略的SWOT分析
    Summary Wallenstam AB (Wallenstam) is a construction company that offers building and property management solutions. The company's services include commercial and residential properties development, housing programs, property investment and management, urban development, property ownership services, …
  • Mitsubishi Corp (8058)：石油・ガス：M&Aディール及び事業提携情報
    Summary Mitsubishi Corp (Mitsubishi) is an integrated company that develops and operates businesses across industry including industrial finance, energy, metals, machinery, chemicals, living essentials, and environmental business. The company manufactures and markets a wide range of products, includ …
  • Comair Limited：企業の戦略・SWOT・財務情報
    Comair Limited - Strategy, SWOT and Corporate Finance Report Summary Comair Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • PT Mitra Adiperkasa Tbk：企業の戦略・SWOT・財務情報
    PT Mitra Adiperkasa Tbk - Strategy, SWOT and Corporate Finance Report Summary PT Mitra Adiperkasa Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Capsugel Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Capsugel Inc (Capsugel) is a contract manufacturing company which designs, develops and manufactures a range of innovative dosage forms. It provides contract services to the biopharmaceutical and consumer health and nutrition industries. The company’s services enable clients to enhance the b …
  • United Therapeutics Corp (UTHR)-医療機器分野：企業M&A・提携分析
    Summary United Therapeutics Corp (UTC) develops and commercializes innovative pharmaceutical products for the treatment of cardiovascular disorders, particularly pulmonary arterial hypertension and infectious diseases. The company's products consist of prostacyclin analogues including Remodulin (tre …
  • Alfred E. Tiefenbacher GmbH & Co KG：製薬・医療：M&Aディール及び事業提携情報
    Summary Alfred E. Tiefenbacher GmbH & Co KG (AET) is an independent pharmaceutical company that focuses on the development of active pharmaceuticals ingredients. It offers products in the forms of tablets, capsules, oral solution, patches, long acting injectables, ophthalmic solution and inhaled the …
  • Cimarex Energy Co (XEC)：石油・ガス：M&Aディール及び事業提携情報
    Summary Cimarex Energy Co (Cimarax) is an independent upstream oil and natural gas company. It carries out the exploration and production of crude oil, natural gas and natural gas liquids (NGLs). The company’s operations are concentrated in two main areas namely the Mid-Continent region consisting o …
  • Rich Pharmaceuticals Inc (RCHA)-製薬・医療分野：企業M&A・提携分析
    Summary Rich Pharmaceuticals Inc (Rich Pharmaceuticals) is a biopharmaceutical company that offers discovery and development of therapies for the treatment of cancer and neurological disorders. The company’s pipeline portfolio offers a lead drug candidate for the treatment of acute myeloid leukemia …
  • The Tata Power Co Ltd (TATAPOWER)：企業の財務・戦略的SWOT分析
    The Tata Power Co Ltd (TATAPOWER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Kingdom Hotel Investments：企業の戦略・SWOT・財務分析
    Kingdom Hotel Investments - Strategy, SWOT and Corporate Finance Report Summary Kingdom Hotel Investments - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Mosaic Brands Ltd (MOZ)：企業の財務・戦略的SWOT分析
    Mosaic Brands Ltd (MOZ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Discovery Communications, Inc.
    Discovery Communications, Inc. - Strategy, SWOT and Corporate Finance Report Summary Discovery Communications, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Exelon Corporation (EXC)：電力：M&Aディール及び事業提携情報
    Summary Exelon Corporation (Exelon) is a utility services holding company operating across the energy value chain comprising power generation, distribution, transmission and energy sales. It generates electricity from diverse sources, including nuclear, fossil fuels and renewable energy. Exelon deli …
  • TD Ameritrade Holding Corporation：企業の戦略・SWOT・財務情報
    TD Ameritrade Holding Corporation - Strategy, SWOT and Corporate Finance Report Summary TD Ameritrade Holding Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆